AU2017359028A1 - Azole amides and amines as alpha V integrin inhibitors - Google Patents
Azole amides and amines as alpha V integrin inhibitors Download PDFInfo
- Publication number
- AU2017359028A1 AU2017359028A1 AU2017359028A AU2017359028A AU2017359028A1 AU 2017359028 A1 AU2017359028 A1 AU 2017359028A1 AU 2017359028 A AU2017359028 A AU 2017359028A AU 2017359028 A AU2017359028 A AU 2017359028A AU 2017359028 A1 AU2017359028 A1 AU 2017359028A1
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- aryl
- heteroaryl
- alkoxy
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 CC(CCN1)*c2c1nc(*)c(C)c2 Chemical compound CC(CCN1)*c2c1nc(*)c(C)c2 0.000 description 11
- ONGSQPYHCQJKPP-JTQLQIEISA-N CCOC(C[C@@H](c(cc1F)ccc1OC)N)=O Chemical compound CCOC(C[C@@H](c(cc1F)ccc1OC)N)=O ONGSQPYHCQJKPP-JTQLQIEISA-N 0.000 description 2
- ZCZVGQCBSJLDDS-UHFFFAOYSA-N C(C1)CNc2c1cccn2 Chemical compound C(C1)CNc2c1cccn2 ZCZVGQCBSJLDDS-UHFFFAOYSA-N 0.000 description 1
- HOFCYSNYAFJTSI-UHFFFAOYSA-N C(CN1)Nc2c1nccc2 Chemical compound C(CN1)Nc2c1nccc2 HOFCYSNYAFJTSI-UHFFFAOYSA-N 0.000 description 1
- ZHZCQJIVIYFJBR-UHFFFAOYSA-O CC(C)(C)OC(N1c2nc(CC[NH2+]C=C(C=N)C(O)=O)ccc2CCC1)=O Chemical compound CC(C)(C)OC(N1c2nc(CC[NH2+]C=C(C=N)C(O)=O)ccc2CCC1)=O ZHZCQJIVIYFJBR-UHFFFAOYSA-O 0.000 description 1
- OYCDOZPKYHGODY-UHFFFAOYSA-N CC(C)(C)OC(N1c2nc(CC[n]3ncc(C=O)c3)ccc2CCC1)=O Chemical compound CC(C)(C)OC(N1c2nc(CC[n]3ncc(C=O)c3)ccc2CCC1)=O OYCDOZPKYHGODY-UHFFFAOYSA-N 0.000 description 1
- WFBFZGNDRINMKW-UHFFFAOYSA-N CC(C)(C)OC(N1c2nc(CC[n]3ncc(CNCCC(C=O)=O)c3)ccc2CCC1)=O Chemical compound CC(C)(C)OC(N1c2nc(CC[n]3ncc(CNCCC(C=O)=O)c3)ccc2CCC1)=O WFBFZGNDRINMKW-UHFFFAOYSA-N 0.000 description 1
- FDLBAAVDMTUIEV-UHFFFAOYSA-O CC(C)(C)OCC(C(C(O)=O)=C[NH2+]CCc1nc2ncccc2cc1)=N Chemical compound CC(C)(C)OCC(C(C(O)=O)=C[NH2+]CCc1nc2ncccc2cc1)=N FDLBAAVDMTUIEV-UHFFFAOYSA-O 0.000 description 1
- PSRJPSMXUOTVLT-UHFFFAOYSA-N CC(C)(C)OCc1n[n](Cc2cc3cccnc3nc2C)cc1C(O)=O Chemical compound CC(C)(C)OCc1n[n](Cc2cc3cccnc3nc2C)cc1C(O)=O PSRJPSMXUOTVLT-UHFFFAOYSA-N 0.000 description 1
- CLZLXFYLOJHNER-OUALLVGRSA-N CC(C[C@@H](c1cc(Cl)cc(Cl)c1)NC(/C(/C=N)=C/NCCCNC1=NCCN1)=O)=O Chemical compound CC(C[C@@H](c1cc(Cl)cc(Cl)c1)NC(/C(/C=N)=C/NCCCNC1=NCCN1)=O)=O CLZLXFYLOJHNER-OUALLVGRSA-N 0.000 description 1
- FIPHWEMVPUSWAP-NSHDSACASA-N CC([C@H](CC(O)=O)NC(c1c[n](CCCN)nc1)=O)=C Chemical compound CC([C@H](CC(O)=O)NC(c1c[n](CCCN)nc1)=O)=C FIPHWEMVPUSWAP-NSHDSACASA-N 0.000 description 1
- HRJQSOJKJWXRSQ-UHFFFAOYSA-N CC1(CC[n]2nccc2C(OC)=O)OCCO1 Chemical compound CC1(CC[n]2nccc2C(OC)=O)OCCO1 HRJQSOJKJWXRSQ-UHFFFAOYSA-N 0.000 description 1
- KOFWTSWEPJHELQ-ARCDLMDQSA-N CCOC(/C(/C=N)=C/NCCc1ccc(CCCN2)c2n1)=O Chemical compound CCOC(/C(/C=N)=C/NCCc1ccc(CCCN2)c2n1)=O KOFWTSWEPJHELQ-ARCDLMDQSA-N 0.000 description 1
- XASYREQXJOHYSW-DQSYWSFLSA-N CCOC(/C(/C=N)=C/NCCc1ccc(CCCN2C(OC(C)(C)C)=O)c2n1)=O Chemical compound CCOC(/C(/C=N)=C/NCCc1ccc(CCCN2C(OC(C)(C)C)=O)c2n1)=O XASYREQXJOHYSW-DQSYWSFLSA-N 0.000 description 1
- BNNATKWJKFKEMX-KUXBLMNESA-N CCOC(C[C@@H](c(cc1)cc(F)c1OC)N(Cc1ccccc1)C(C)c1ccccc1)=O Chemical compound CCOC(C[C@@H](c(cc1)cc(F)c1OC)N(Cc1ccccc1)C(C)c1ccccc1)=O BNNATKWJKFKEMX-KUXBLMNESA-N 0.000 description 1
- IFURMCASQHKLTN-UHFFFAOYSA-N CCOC(c1c(COC(C)(C)C)[n](CCCC(C)=O)nc1)=O Chemical compound CCOC(c1c(COC(C)(C)C)[n](CCCC(C)=O)nc1)=O IFURMCASQHKLTN-UHFFFAOYSA-N 0.000 description 1
- NLLRKTYQEREMAY-UHFFFAOYSA-N CC[n]1nc(C(F)(F)F)c(O)c1 Chemical compound CC[n]1nc(C(F)(F)F)c(O)c1 NLLRKTYQEREMAY-UHFFFAOYSA-N 0.000 description 1
- GIYPCBPERKKRML-UHFFFAOYSA-N CNC1=NCCCN1 Chemical compound CNC1=NCCCN1 GIYPCBPERKKRML-UHFFFAOYSA-N 0.000 description 1
- OFUZKVDIJVKIAD-SNVBAGLBSA-N CN[C@H](CC(OC)=O)c1cc(Cl)cc(Cl)c1 Chemical compound CN[C@H](CC(OC)=O)c1cc(Cl)cc(Cl)c1 OFUZKVDIJVKIAD-SNVBAGLBSA-N 0.000 description 1
- ALBBQFWHUCTZFM-UHFFFAOYSA-N CNc1nc2ccccc2[nH]1 Chemical compound CNc1nc2ccccc2[nH]1 ALBBQFWHUCTZFM-UHFFFAOYSA-N 0.000 description 1
- ZYXHZCQMCOVXJW-UHFFFAOYSA-N CNc1ncc[nH]1 Chemical compound CNc1ncc[nH]1 ZYXHZCQMCOVXJW-UHFFFAOYSA-N 0.000 description 1
- SVEUVITYHIHZQE-UHFFFAOYSA-N CNc1ncccc1 Chemical compound CNc1ncccc1 SVEUVITYHIHZQE-UHFFFAOYSA-N 0.000 description 1
- JSPUHTBZBCNNOB-FQEVSTJZSA-N COc1ccc([C@H](CC(O)=O)NC(c2c(CO)[n](CCc3ccc(CCCN4)c4n3)nc2)=O)cc1F Chemical compound COc1ccc([C@H](CC(O)=O)NC(c2c(CO)[n](CCc3ccc(CCCN4)c4n3)nc2)=O)cc1F JSPUHTBZBCNNOB-FQEVSTJZSA-N 0.000 description 1
- VDAZPCGWCIHHNX-UHFFFAOYSA-N C[IH]c1c(CCCN2)c2ncc1 Chemical compound C[IH]c1c(CCCN2)c2ncc1 VDAZPCGWCIHHNX-UHFFFAOYSA-N 0.000 description 1
- CMESAAGBVFDAEX-UHFFFAOYSA-N Cc(cc1)nc2c1OCCCN2 Chemical compound Cc(cc1)nc2c1OCCCN2 CMESAAGBVFDAEX-UHFFFAOYSA-N 0.000 description 1
- FOVXANGOLMXKES-UHFFFAOYSA-N Cc(cc1F)ccc1OC Chemical compound Cc(cc1F)ccc1OC FOVXANGOLMXKES-UHFFFAOYSA-N 0.000 description 1
- OACBSRXQDODDAJ-UHFFFAOYSA-N Cc1c[n](CCCN2)c2n1 Chemical compound Cc1c[n](CCCN2)c2n1 OACBSRXQDODDAJ-UHFFFAOYSA-N 0.000 description 1
- NYXBAKOUWKGHEY-UHFFFAOYSA-N Cc1c[n](CCN2)c2n1 Chemical compound Cc1c[n](CCN2)c2n1 NYXBAKOUWKGHEY-UHFFFAOYSA-N 0.000 description 1
- UJMYPWJFZKPGLR-UHFFFAOYSA-N Cc1cc(C)n[n]1-c1cc(C(CC(O)=O)NC(c2c(CO)[nH]nc2)=O)ccc1 Chemical compound Cc1cc(C)n[n]1-c1cc(C(CC(O)=O)NC(c2c(CO)[nH]nc2)=O)ccc1 UJMYPWJFZKPGLR-UHFFFAOYSA-N 0.000 description 1
- RYMMNSVHOKXTNN-UHFFFAOYSA-N Cc1cc(Cl)cc(Cl)c1 Chemical compound Cc1cc(Cl)cc(Cl)c1 RYMMNSVHOKXTNN-UHFFFAOYSA-N 0.000 description 1
- OBVBXJCBROVJET-XIPJMBFMSA-N Cc1ccc([C@H](CC(O)=O)N(C)C(/C(/C=N)=C/NCCc2ccc(CCCN3)c3n2)=O)cc1F Chemical compound Cc1ccc([C@H](CC(O)=O)N(C)C(/C(/C=N)=C/NCCc2ccc(CCCN3)c3n2)=O)cc1F OBVBXJCBROVJET-XIPJMBFMSA-N 0.000 description 1
- VJYXZJGDFJJDGF-UHFFFAOYSA-N Cc1cccc(C(F)(F)F)c1 Chemical compound Cc1cccc(C(F)(F)F)c1 VJYXZJGDFJJDGF-UHFFFAOYSA-N 0.000 description 1
- WRNXOOXIPSTAGJ-UHFFFAOYSA-N Cc1cccc(OC(F)(F)F)c1 Chemical compound Cc1cccc(OC(F)(F)F)c1 WRNXOOXIPSTAGJ-UHFFFAOYSA-N 0.000 description 1
- AVTNZJVZWSMREN-UHFFFAOYSA-N Cc1cccc(Oc2cc(Cl)cc(Cl)c2)c1 Chemical compound Cc1cccc(Oc2cc(Cl)cc(Cl)c2)c1 AVTNZJVZWSMREN-UHFFFAOYSA-N 0.000 description 1
- RKBGOCRMVOYIRS-UHFFFAOYSA-N Cc1nc(NCCCC2)c2cc1 Chemical compound Cc1nc(NCCCC2)c2cc1 RKBGOCRMVOYIRS-UHFFFAOYSA-N 0.000 description 1
- NXMFJCRMSDRXLD-UHFFFAOYSA-N Nc1ncccc1C=O Chemical compound Nc1ncccc1C=O NXMFJCRMSDRXLD-UHFFFAOYSA-N 0.000 description 1
- SQPKBLHEJSNBRN-UHFFFAOYSA-N OC(c1c[n](CCC2=CC=C(CCCN3)C3N2)nc1)=O Chemical compound OC(c1c[n](CCC2=CC=C(CCCN3)C3N2)nc1)=O SQPKBLHEJSNBRN-UHFFFAOYSA-N 0.000 description 1
- MRWVQDCFSFQSRS-UHFFFAOYSA-N OC(c1c[n](CCc2ccc(CCCN3)c3n2)nn1)=O Chemical compound OC(c1c[n](CCc2ccc(CCCN3)c3n2)nn1)=O MRWVQDCFSFQSRS-UHFFFAOYSA-N 0.000 description 1
- YHONSIRGUBUUKO-UHFFFAOYSA-N OC(c1ccn[n]1CCc1nc(NCCC2)c2cc1)=O Chemical compound OC(c1ccn[n]1CCc1nc(NCCC2)c2cc1)=O YHONSIRGUBUUKO-UHFFFAOYSA-N 0.000 description 1
- GVBHDJARFSGUFZ-UHFFFAOYSA-N Oc(cn1)c(-c2ccccc2)[n]1O Chemical compound Oc(cn1)c(-c2ccccc2)[n]1O GVBHDJARFSGUFZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662418838P | 2016-11-08 | 2016-11-08 | |
| US62/418,838 | 2016-11-08 | ||
| PCT/US2017/060390 WO2018089358A1 (en) | 2016-11-08 | 2017-11-07 | Azole amides and amines as alpha v integrin inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2017359028A1 true AU2017359028A1 (en) | 2019-06-20 |
Family
ID=60409437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017359028A Abandoned AU2017359028A1 (en) | 2016-11-08 | 2017-11-07 | Azole amides and amines as alpha V integrin inhibitors |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10851098B2 (enExample) |
| EP (1) | EP3538527B1 (enExample) |
| JP (1) | JP7128811B2 (enExample) |
| KR (1) | KR102510858B1 (enExample) |
| CN (1) | CN110167933B (enExample) |
| AU (1) | AU2017359028A1 (enExample) |
| BR (1) | BR112019009245A2 (enExample) |
| CA (1) | CA3042684A1 (enExample) |
| EA (1) | EA201991121A1 (enExample) |
| ES (1) | ES2898835T3 (enExample) |
| IL (1) | IL266465A (enExample) |
| MA (1) | MA46746A (enExample) |
| MX (1) | MX2019005234A (enExample) |
| WO (1) | WO2018089358A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109996541A (zh) | 2016-09-07 | 2019-07-09 | 普利安特治疗公司 | N-酰基氨基酸化合物及其使用方法 |
| CA3045491A1 (en) | 2016-12-29 | 2018-07-19 | Indalo Therapeutics, Inc. | Integrin antagonists |
| EP4159727B1 (en) | 2017-02-28 | 2026-04-08 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| US11046685B2 (en) | 2017-02-28 | 2021-06-29 | Morphic Therapeutic, Inc. | Inhibitors of (α-v)(β-6) integrin |
| AU2019327475B2 (en) | 2018-08-29 | 2025-06-05 | Morphic Therapeutic, Inc. | INHIBITING αV β6 INTEGRIN |
| PT3844162T (pt) | 2018-08-29 | 2025-03-28 | Morphic Therapeutic Inc | Inibidores da integrina alfa v beta6 |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| ES2987796T3 (es) | 2018-10-30 | 2024-11-18 | Gilead Sciences Inc | Derivados de N-benzoil-fenilalanina como inhibidores de la integrina alfa4beta7 para el tratamiento de enfermedades inflamatorias |
| DK3873884T3 (da) | 2018-10-30 | 2025-02-17 | Gilead Sciences Inc | 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme |
| WO2020092394A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
| WO2020092401A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN |
| AU2020329207B2 (en) | 2019-08-14 | 2024-02-29 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
| GB202010626D0 (en) | 2020-07-10 | 2020-08-26 | Univ Nottingham | Compound |
| US20240174603A1 (en) * | 2021-02-08 | 2024-05-30 | Rappta Therapeutics Oy | Modulators of protein phosphatase 2a (pp2a) and methods using same |
| IL305752A (en) * | 2021-03-10 | 2023-11-01 | Dice Molecules Sv Inc | INTEGRIN INHIBITORS OF ALPHA V BETA 6 AND ALPHA V BETA 1 AND THEIR USES |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5849736A (en) * | 1993-11-24 | 1998-12-15 | The Dupont Merck Pharmaceutical Company | Isoxazoline and isoxazole fibrinogen receptor antagonists |
| ZA972195B (en) | 1996-03-15 | 1998-09-14 | Du Pont Merck Pharma | Spirocycle integrin inhibitors |
| JP2001524481A (ja) * | 1997-11-26 | 2001-12-04 | デュポン ファーマシューティカルズ カンパニー | αＶβ３アンタゴニストとしての１，３，４−チアジアゾール類および１，３，４−オキサジアゾール類 |
| EP1047425A4 (en) | 1997-12-17 | 2009-04-22 | Merck & Co Inc | INTEGRIN RECEPTOR ANTAGONISTS |
| AU748621B2 (en) | 1998-08-13 | 2002-06-06 | Merck & Co., Inc. | Integrin receptor antagonists |
| DE60035779T2 (de) * | 1999-06-02 | 2008-04-30 | Merck & Co., Inc. | Alpha v integrin-rezeptor antagonisten |
| JP2004511434A (ja) | 2000-06-15 | 2004-04-15 | ファルマシア・コーポレーション | インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸 |
| WO2002060438A1 (en) | 2001-01-29 | 2002-08-08 | 3-Dimensional Pharmaceuticals, Inc. | Substituted indoles and their use as integrin antagonists |
| EP1539739B1 (en) | 2002-08-16 | 2010-11-24 | Janssen Pharmaceutica NV | Piperidinyl compounds that selectively bind integrins |
| ES2308227T3 (es) | 2003-10-01 | 2008-12-01 | Merck Patent Gmbh | Antagonistas de integrina alfavbeta3 y alfavbeta6 como agentes antifibroticos. |
| WO2006108040A1 (en) | 2005-04-05 | 2006-10-12 | Janssen Pharmaceutica, N.V. | Substituted indoles and their use as integrin antagonists |
| JP2009539815A (ja) | 2006-06-09 | 2009-11-19 | アストラゼネカ アクチボラグ | 固形腫瘍の治療用のａ５ｂ１アンタゴニストとしてのＮ−（ベンゾイル）−Ｏ−［２−（ピリジン−２−イルアミノ）エチル］−Ｌ−チロシン誘導体と関連化合物 |
| WO2008125811A1 (en) | 2007-04-11 | 2008-10-23 | Astrazeneca Ab | N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS |
| ITFI20100019A1 (it) * | 2010-02-12 | 2011-08-13 | Univ Firenze | Inibitori peptidomimetici di integrine basati sull'1,2,3-triazolo per la diagnosi e terapia dei tumori. |
| BR112015004427A2 (pt) | 2012-10-26 | 2017-07-04 | Hoffmann La Roche | compostos , métodos para o tratamento de um estado inflamatório , da artrite reumatóide , da asma , de um distúrbio imunológico e de um distúrbio imune e composição farmacêutica |
| EP3266782B1 (en) * | 2013-02-07 | 2019-10-30 | SciFluor Life Sciences, Inc. | Fluorinated integrin antagonists |
| GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201417018D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| EP3925959A1 (en) | 2015-02-19 | 2021-12-22 | OcuTerra Therapeutics, Inc. | Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof |
| AU2016228852A1 (en) | 2015-03-10 | 2017-10-19 | The Regents Of The University Of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
| PT3538525T (pt) * | 2016-11-08 | 2022-08-16 | Bristol Myers Squibb Co | Ácidos propiónicos 3-substituídos por inibidores de alfa v integrina |
-
2017
- 2017-11-07 AU AU2017359028A patent/AU2017359028A1/en not_active Abandoned
- 2017-11-07 CA CA3042684A patent/CA3042684A1/en not_active Abandoned
- 2017-11-07 MX MX2019005234A patent/MX2019005234A/es unknown
- 2017-11-07 EP EP17801235.7A patent/EP3538527B1/en active Active
- 2017-11-07 BR BR112019009245A patent/BR112019009245A2/pt not_active Application Discontinuation
- 2017-11-07 MA MA046746A patent/MA46746A/fr unknown
- 2017-11-07 CN CN201780082144.8A patent/CN110167933B/zh active Active
- 2017-11-07 ES ES17801235T patent/ES2898835T3/es active Active
- 2017-11-07 US US16/347,829 patent/US10851098B2/en active Active
- 2017-11-07 WO PCT/US2017/060390 patent/WO2018089358A1/en not_active Ceased
- 2017-11-07 KR KR1020197016076A patent/KR102510858B1/ko active Active
- 2017-11-07 JP JP2019523847A patent/JP7128811B2/ja active Active
- 2017-11-07 EA EA201991121A patent/EA201991121A1/ru unknown
-
2019
- 2019-05-06 IL IL266465A patent/IL266465A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20190256513A1 (en) | 2019-08-22 |
| EP3538527B1 (en) | 2021-10-13 |
| KR20190076030A (ko) | 2019-07-01 |
| IL266465A (en) | 2019-07-31 |
| ES2898835T3 (es) | 2022-03-09 |
| EP3538527A1 (en) | 2019-09-18 |
| WO2018089358A1 (en) | 2018-05-17 |
| CA3042684A1 (en) | 2018-05-17 |
| US10851098B2 (en) | 2020-12-01 |
| MX2019005234A (es) | 2019-08-12 |
| KR102510858B1 (ko) | 2023-03-15 |
| CN110167933B (zh) | 2022-06-21 |
| EA201991121A1 (ru) | 2019-11-29 |
| BR112019009245A2 (pt) | 2019-07-16 |
| CN110167933A (zh) | 2019-08-23 |
| JP2019537603A (ja) | 2019-12-26 |
| MA46746A (fr) | 2019-09-18 |
| JP7128811B2 (ja) | 2022-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11639353B2 (en) | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | |
| EP3538527B1 (en) | Azole amides and amines as alpha v integrin inhibitors | |
| US11028071B2 (en) | Indazole derivatives as alpha v integrin antagonists | |
| US11884661B2 (en) | 3-substituted propionic acids as αV integrin inhibitors | |
| US10717736B2 (en) | Pyrrole amides as alpha V integrin inhibitors | |
| HK40009959B (en) | 3-substituted propionic acids as alpha v integrin inhibitors | |
| HK40009959A (en) | 3-substituted propionic acids as alpha v integrin inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |